• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer

by MM360 Staff | Apr 29, 2025 | Uncategorized

Source: CureToday articles Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer. Read More

TAR-200 Shows High Response Rates in Bladder Cancer Subset

by MM360 Staff | Apr 29, 2025 | Uncategorized

Source: CureToday articles TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study. Read More

A Fellow Cancer Survivor Gives Me a Useful Message

by MM360 Staff | Apr 29, 2025 | Uncategorized

Source: CureToday articles A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time. Read More

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

by MM360 Staff | Apr 29, 2025 | Uncategorized

Source: CureToday articles The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers. Read More

FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer

by MM360 Staff | Apr 29, 2025 | Uncategorized

Source: CureToday articles INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer. Read More

SIRT With 90Y Resin Microspheres Provides Benefit in GIST Liver Metastases

by MM360 Staff | Apr 29, 2025 | Uncategorized

Source: CureToday articles SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver metastases resistant to TKI therapy. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT